睡眠改善型功能食品对慢性失眠人群睡眠质量的影响

注册号:

Registration number:

ChiCTR2600125660 

最近更新日期:

Date of Last Refreshed on:

2026-05-29 10:16:22 

注册时间:

Date of Registration:

2026-05-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

睡眠改善型功能食品对慢性失眠人群睡眠质量的影响

Public title:

Effect of Sleep-improving Functional Foods on Sleep Quality in Patients with Chronic Insomnia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

睡眠改善型功能食品对慢性失眠人群睡眠质量的影响

Scientific title:

Effect of Sleep-improving Functional Foods on Sleep Quality in Patients with Chronic Insomnia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陆文伟 

研究负责人:

王军 

Applicant:

Wenwei Lu 

Study leader:

Jun Wang 

申请注册联系人电话:

Applicant telephone:

+86 510 85912155

研究负责人电话:

Study leader's
telephone:

+86 510 83219310

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

luwenwei@jiangnan.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

woodfish2@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省无锡市蠡湖大道1800号江南大学

研究负责人通讯地址:

江苏省无锡滨湖区钱荣路156号

Applicant address:

Jiangnan University, 1800 Lihu Avenue, Wuxi, Jiangsu

Study leader's address:

No. 156 Qianrong Road, Binhu District, Wuxi, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江南大学

Applicant's institution:

Jiangnan University

研究负责人所在单位:

无锡市精神卫生中心

Affiliation of the Leader:

Wuxi Mental Health Center

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

WXMHCIRB2026LLky100

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

无锡市精神卫生中心伦理委员会

Name of the ethic committee:

Wuxi mental health center

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-23 00:00:00

伦理委员会联系人:

计樱莹

Contact Name of the ethic committee:

Ji Yingying

伦理委员会联系地址:

江苏省无锡滨湖区钱荣路156号

Contact Address of the ethic committee:

No. 156 Qianrong Road, Binhu District, Wuxi, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 510 83219310

伦理委员会联系人邮箱:

Contact email of the ethic committee:

miaomiao1987@163.com

研究实施负责(组长)单位:

无锡市精神卫生中心

Primary sponsor:

Wuxi Mental Health Center

研究实施负责(组长)单位地址:

江苏省无锡滨湖区钱荣路156号

Primary sponsor's address:

No. 156 Qianrong Road, Binhu District, Wuxi, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

无锡市精神卫生中心

具体地址:

江苏省无锡滨湖区钱荣路156号

Institution
hospital:

Wuxi Mental Health Center

Address:

No. 156 Qianrong Road, Binhu District, Wuxi, Jiangsu Province

经费或物资来源:

中华人民共和国科学技术部

Source(s) of funding:

Ministry of Science and Technology of the People´s Republic of China

研究疾病:

慢性失眠症;失眠障碍  

Target disease:

Chronic insomnia; insomnia disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本试验以失眠人群为研究对象,主要评估该功能食品对主观睡眠质量的改善效果,次要评估该功能食品对失眠患者其他睡眠相关指标以及伴发的焦虑/抑郁症状的改善效果。通过检测血清生物标志物含量、血清/粪便差异代谢物和肠道菌群分布探究此功能食品对神经递质、炎症因子、关键代谢通路及肠道菌群的调控作用。  

Objectives of Study:

This experiment takes the insomnia population as the research object, mainly evaluates the improvement effect of the functional food on subjective sleep quality, and secondarily evaluates the improvement effect of the functional food on other sleep related indicators and accompanying anxiety / depression symptoms of insomnia patients. The regulatory effects of this functional food on neurotransmitters, inflammatory factors, key metabolic pathways and intestinal flora were explored by detecting the content of serum biomarkers, serum / fecal differential metabolites and intestinal flora distribution.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.存在其他类型的严重睡眠障碍,如严重睡眠呼吸暂停综合征(STOP-Bang评分≥4分)、严重周期性肢体运动障碍等;
2.经精神科医师评估,符合DSM-5标准中主要精神疾病诊断标准者,包括焦虑障碍、抑郁障碍、双相情感障碍、精神分裂症及其他严重精神障碍者;
3.合并患有严重的心、脑、肝、肾、造血系统原发性疾病, 或其他急性病、传染病、恶性肿瘤;
4.正式入组前1周内曾服用任何抗抑郁药、抗精神病药、镇静安眠药等药物,正式入组前1周内过度饮酒;
5.正式入组前 2 周内有倒班工作、跨时区长途旅行或显著作息紊乱者;近 1个月经历重大生活应激事件(离异、丧亲、重大手术等)者;
6.妊娠期或哺乳期女性;
7.对功能食品(灵芝、黄芪、丹参、大枣、知母、香附)过敏或不耐受;
8.认知功能障碍无法配合完成量表评估者,或无法保证试验期间不私自使用其他助眠药物者;

Exclusion criteria:

1. There are other types of severe sleep disorders, such as severe sleep apnea syndrome (stop Bang score >= 4), severe periodic limb movement disorders, etc; 2. According to the evaluation of psychiatrists, those who meet the diagnostic criteria of major mental diseases in dsm-5 standards include those with anxiety disorder, depression disorder, bipolar disorder, schizophrenia and other serious mental disorders; 3. Complicated with serious primary diseases of heart, brain, liver, kidney, hematopoietic system, or other acute diseases, infectious diseases, malignant tumors; 4. Had taken any antidepressants, antipsychotics, sedative hypnotics and other drugs within 1 week before formal enrollment, and had excessive alcohol consumption within 1 week before formal enrollment; 5. Those who had shift work, long-distance travel across time zones or significant work and rest disturbances within 2 weeks before formal enrollment; Those who have experienced major life stress events (divorce, bereavement, major surgery, etc.) in the past 1 month; 6. Pregnant or lactating women; 7. Allergic or intolerant to functional foods (Ganoderma lucidum, Astragalus membranaceus, Salvia miltiorrhiza, jujube, Anemarrhena asphodeloides, Cyperus rotundus); 8. Those with cognitive impairment who cannot cooperate with the assessment of the scale, or who cannot guarantee that they will not use other sleeping aid drugs without permission during the trial;

研究实施时间:

Study execute time:

From 2026-05-07 00:00:00 To 2026-12-15 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-03 00:00:00 To 2026-10-10 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

60

Group:

Test group

Sample size:

干预措施:

植物提取物粉干预

干预措施代码:

Intervention:

Intervention of plant extract powder

Intervention code:

组别:

对照组

样本量:

60

Group:

Control group

Sample size:

干预措施:

安慰剂干预

干预措施代码:

Intervention:

Placebo intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

无锡市精神卫生中心 

单位级别:

三级甲等 

Institution
hospital:

Wuxi Mental Health Center

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

complete blood count

Type:

Secondary indicator

测量时间点:

第0、4周

测量方法:

Measure time point of outcome:

Week 0 and 4

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index, PSQI

Type:

Primary indicator

测量时间点:

第0、4周

测量方法:

Measure time point of outcome:

Week 0 and 4

Measure method:

指标中文名:

失眠严重程度指数量表

指标类型:

次要指标

Outcome:

Insomnia Severity Index, ISI

Type:

Secondary indicator

测量时间点:

第0、2、4周

测量方法:

Measure time point of outcome:

Weeks 0, 2, and 4

Measure method:

指标中文名:

粪便宏基因组学

指标类型:

次要指标

Outcome:

Fecal metagenomics

Type:

Secondary indicator

测量时间点:

第0、4周

测量方法:

Measure time point of outcome:

Week 0 and 4

Measure method:

指标中文名:

神经递质和免疫因子检测

指标类型:

次要指标

Outcome:

Neurotransmitter and immune factor detection

Type:

Secondary indicator

测量时间点:

第0、4周

测量方法:

Measure time point of outcome:

Week 0 and 4

Measure method:

指标中文名:

血清非靶代谢组学

指标类型:

次要指标

Outcome:

Serum untargeted metabolomics

Type:

Secondary indicator

测量时间点:

第0、4周

测量方法:

Measure time point of outcome:

Week 0 and 4

Measure method:

指标中文名:

广泛性焦虑量表

指标类型:

次要指标

Outcome:

Generalized Anxiety Disorder 7-item scale, GAD-7

Type:

Secondary indicator

测量时间点:

第0、2、4周

测量方法:

Measure time point of outcome:

Weeks 0, 2, and 4

Measure method:

指标中文名:

PPG睡眠监测

指标类型:

次要指标

Outcome:

PPG Sleep Monitoring

Type:

Secondary indicator

测量时间点:

测量方法:

设备监测;问卷填写

Measure time point of outcome:

Measure method:

Equipment monitoring; Questionnaire filling

指标中文名:

血生化

指标类型:

次要指标

Outcome:

blood biochemistry

Type:

Secondary indicator

测量时间点:

第0、4周

测量方法:

Measure time point of outcome:

Week 0 and 4

Measure method:

指标中文名:

抑郁自评工具量表

指标类型:

次要指标

Outcome:

Patient Health Questionnaire-9, PHQ-9

Type:

Secondary indicator

测量时间点:

第0、2、4周

测量方法:

Measure time point of outcome:

Weeks 0, 2, and 4

Measure method:

指标中文名:

Epworth嗜睡量表

指标类型:

次要指标

Outcome:

Epworth Sleepiness Scale, ESS

Type:

Secondary indicator

测量时间点:

第0、2、4周

测量方法:

Measure time point of outcome:

Weeks 0, 2, and 4

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计人员使用计算机软件产生随机数字进行分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Statisticians used computer software to generate random numbers for grouping

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF collection

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-05-29 10:16:05